Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clinuvel PharmaceuticalsCLVLF 87 Cash Ratio is 13.05 as of Dec. 2025, which is 42% above its 10-year median of 9.18. GuruFocus rates CLVLF with a GF Score™ of 87/100 and a GF Value™ of $12.49 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,384 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 85.98% on this metric.
Clinuvel Pharmaceuticals has a Cash Ratio of 13.05. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Clinuvel Pharmaceuticals's Cash Ratio or its related term are showing as below:
CLVLF'
s Cash Ratio Range Over the Past 10 Years
Min: 5.94 Med: 9.18 Max: 16.72
Current: 13.05
During the past 13 years, Clinuvel Pharmaceuticals's highest Cash Ratio was 16.72. The lowest was 5.94. And the median was 9.18.
CLVLF's Cash Ratio is ranked better than 85.98% of 1384
companies
in the Biotechnology industry
Industry Median: 2.93
vs CLVLF: 13.05
Clinuvel Pharmaceuticals (OTCPK:CLVLF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Clinuvel Pharmaceuticals Cash Ratio Related Terms
Clinuvel Pharmaceuticals Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinuvel Pharmaceuticals (CLVLF) has a Cash Ratio of 13.05 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Clinuvel Pharmaceuticals and its competitors. This is 42% above median its historical median of 9.18. Over the past decade, Clinuvel Pharmaceuticals' Cash Ratio has ranged from 5.94 to 16.72. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #194 out of 1384 companies in the Biotechnology industry, placing it in the top 14%.
Is Clinuvel Pharmaceuticals' Cash Ratio too high?
Clinuvel Pharmaceuticals' current Cash Ratio of 13.05 is 42% above median its 10-year median of 9.18. Over the past 10 years, this metric has ranged from a low of 5.94 to a high of 16.72. The Biotechnology industry median Cash Ratio is 2.93. Clinuvel Pharmaceuticals' value of 13.05 is 345.4% above this industry median. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #194 out of 1384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #194 out of 1384 companies for Cash Ratio. This places Clinuvel Pharmaceuticals in the top 14% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. Clinuvel Pharmaceuticals' value of 13.05 is 345.4% above this benchmark. Historically, Clinuvel Pharmaceuticals' own Cash Ratio has ranged from 5.94 to 16.72 over the past decade. While the company's 10-year median is 9.18 vs. the industry median of 2.93, Clinuvel Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinuvel Pharmaceuticals's current Cash Ratio of 13.05 is 345.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Clinuvel Pharmaceuticals and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinuvel Pharmaceuticals's current Cash Ratio is 13.05, which is 42% above median its own 10-year median of 9.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals (CLVLF) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.49, compared to a current price of $6.37 — trading 49% below its estimated fair value. The current Cash Ratio is 13.05, which is 42% above median its 10-year median of 9.18 and 345.4% above the Biotechnology industry median of 2.93. Clinuvel Pharmaceuticals' overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (CLVLF), the current Cash Ratio is 13.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinuvel Pharmaceuticals (CLVLF) Overvalued in 2026?
Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued.
The current stock price of $6.37 is trading 49% below its estimated GF Value™ of $12.49.
GuruFocus considers Clinuvel Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for CLVLF:
Cash Ratio: 13.05 (42% above median its 10-year median of 9.18)
GF Value™: $12.49 vs. price of $6.37 (49% below fair value)
Industry Position: 345.4% above the Biotechnology median (#194 of 1384)
No single metric tells the full story. See the CLVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
87GF Score
Get the complete analysis for CLVLF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLVLF has been successfully added to your 
